AstraZeneca Results Presentation Deck

Imfinzi new launches continue to drive near-term growth HIMALAYA unresectable HCC TOPAZ-1 1L BTC POSEIDON 1L NSCLC Oncology - key Imfinzi opportunities in focus Strong launch uptake, robust LCM pipeline supporting continued IO leadership ● CEO Opening Remarks ● ● First dual 10 regimen Unprecedented 4-year OS data presented at ESMO World GI 2023 Financial Results First, innovative 10 regimen in BTC Established SoC in US within months EU, JP launch trajectory outpacing US Encouraging launch uptake in crowded competitive landscape New launch momentum (POSEIDON, HIMALAYA, TOPAZ) builds on top of sustained leadership in PACIFIC, CASPIAN H2 '23 Oncology H2 '23 BioPharmaceuticals Rare Disease LCM HLRs in 2023 contribute to sustained, mid-term Imfinzi growth AEGEAN (early resec. NSCLC) Significant improvement in EFS vs neoadjuvant CTx DUO-O (1L ovarian) Further improvement with Lynparza + Imfinzi CEO Closing Remarks DUO-E (1L endometrial) Greater benefit in Imfinzi + Lynparza + CTx arm MATTERHORN (Gastric and GEJ) First IO + FLOT to demonstrate clinical benefit PACIFIC-2 (Stg. III unresec. NSCLC) Potential to move 10 upfront + CCRT EMERALD-1 (locoregional HCC) Potential to improve PFS vs TACE therapy LCM = lifecycle management; 10 = immuno-oncology; HCC = hepatocellular carcinoma; OS = overall survival; ESMO = European Society of Medical Oncology; GI = gastrointestinal; GEJ = gastroesophageal junction; BTC = biliary tract cancer; SoC = 16 standard of care; JP = Japan; NSCLC = non-small cell lung cancer; HLR = high-level results; EFS = event-free survival; CTX = chemotherapy; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; CCRT = concurrent chemoradiotherapy; PFS = progression free survival; TACE = transarterial chemoembolisation. 4

View entire presentation